Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning
August 22 2022 - 9:00AM
Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the
developer of the innovative alpha-radiation cancer therapy Alpha
DaRT™, and MIM Software Inc. (“MIM Software”), a leading global
provider of medical imaging software, announced a collaboration
between the two companies to provide treatment planning software
for clinical sites using the Alpha DaRT therapy.
Under the terms of the agreement, the parties will collaborate
on the use of MIM’s software suite, including MIM Symphony and
MIMcloud®, for development of new features and support for the
Alpha DaRT across multiple potential indications, integration into
all clinical trials involving the Alpha DaRT, and bundling the MIM
software with the Alpha DaRT for future commercial sales in
territories where the Alpha DaRT and MIM’s software are both
approved.
The MIM Symphony treatment planning software guides clinicians
through an easy step-by-step process to place Alpha DaRT sources
precisely and create a patient-personalized treatment plan. MIM’s
proprietary image manipulation capabilities, including MIM
ReSlicer, and process and data management with MIM Workflows and
MIMcloud, allow MIM Symphony to support treatment planning flexibly
across multiple disease sites. Versatile guidance capabilities,
including the ability to create custom 3D-printed access devices,
assist in Alpha DaRT placement for challenging targets.
“We are thrilled to be taking this next step in our longstanding
relationship with MIM,” noted Uzi Sofer, CEO of Alpha Tau. “While
working with MIM for the past few years, we have seen this
software’s ability to make treatment planning simpler and more
powerful for the clinicians using the Alpha DaRT, and we are very
excited to integrate our technologies and deliver the best
therapeutic care for cancer patients. We continue to see increasing
response rates in our clinical trials, culminating in our most
recent data release from our U.S. pilot study treating cutaneous
cancers, where we observed a 100% complete response rates at 12 and
24 weeks after treatment. We believe that our improved treatment
planning capabilities, including those developed with our
colleagues at MIM, have played an important part in that
achievement.” Alpha Tau Chief Operating Officer, Amnon Gat, added,
“Our experience with the MIM team has been fantastic, and has
instilled confidence that we can continue to develop together new
treatment planning methods and workflows for our pipeline
indications such as cancers of the brain, pancreas and liver.”
“Our collaboration with Alpha Tau is an excellent opportunity
for MIM to impact radiotherapy and patient outcomes,” said Andy
Nelson, CEO of MIM Software. “We are very pleased with the response
rates and are excited to be involved in providing an enhanced
patient experience with Alpha DaRT.” MIM Software Chief Scientific
Officer, Jon Piper, added, “It’s been wonderful working together
with Alpha Tau towards improving outcomes for patients whose
options are limited today. We are hopeful that the planning,
quality assurance, and standardization that MIM provides will allow
clinicians to realize the potential of this transformational
modality.”
About Alpha DaRTAlpha DaRT (Diffusing
Alpha-emitters Radiation Therapy) is designed to enable highly
potent and conformal alpha-irradiation of solid tumors by
intratumoral delivery of radium-224 impregnated sources. When the
radium decays, its short-lived daughters are released from the
sources and disperse while emitting high-energy alpha particles
with the goal of destroying the tumor. Since the alpha-emitting
atoms diffuse only a short distance, Alpha DaRT aims to mainly
affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical Ltd.Founded in 2016,
Alpha Tau is an Israeli medical device company that focuses on
research, development, and potential commercialization of the Alpha
DaRT for the treatment of solid tumors. The technology was
initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari
from Tel Aviv University.
About MIM Software Inc.MIM Software is
committed to enhancing patient care by providing customer-centered
and innovative medical imaging and planning solutions in the fields
of Radiation Oncology, Brachytherapy, Radiology, Nuclear Medicine,
Urology, Neuroimaging, and Cardiac Imaging. The company’s products
are used in over 5,000 centers worldwide.
MIM Software Inc. is a privately-held company headquartered in
Cleveland, OH, with international offices in Beijing, Chengdu, and
Brussels.
To learn more, visit mimsoftware.com.
Forward-Looking Statements This press release
includes "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. When used herein,
words including "anticipate," "being," "will," "plan," "may,"
"continue," and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Alpha Tau's current expectations and various
assumptions. Alpha Tau believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain. Alpha
Tau may not realize its expectations, and its beliefs may not prove
correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation: (i)
Alpha Tau's ability to receive regulatory approval for its Alpha
DaRT technology or any future products or product candidates; (ii)
Alpha Tau's limited operating history; (iii) Alpha Tau's incurrence
of significant losses to date; (iv) Alpha Tau's need for additional
funding and ability to raise capital when needed; (v) Alpha Tau's
limited experience in medical device discovery and development;
(vi) Alpha Tau's dependence on the success and commercialization of
the Alpha DaRT technology; (vii) the failure of preliminary data
from Alpha Tau's clinical studies to predict final study results;
(viii) failure of Alpha Tau's early clinical studies or preclinical
studies to predict future clinical studies; (ix) Alpha Tau's
ability to enroll patients in its clinical trials; (x) undesirable
side effects caused by Alpha Tau's Alpha DaRT technology or any
future products or product candidates; (xi) Alpha Tau's exposure to
patent infringement lawsuits; (xii) Alpha Tau's ability to comply
with the extensive regulations applicable to it; (xiii) the ability
to meet Nasdaq's listing standards; (xiv) costs related to being a
public company; (xv) changes in applicable laws or regulations;
(xix) impacts from the COVID-19 pandemic; and the other important
factors discussed under the caption "Risk Factors" in Alpha Tau's
annual report filed on form 20-F with the SEC on March 28, 2022,
and other filings that Alpha Tau may make with the United States
Securities and Exchange Commission. These and other important
factors could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While Alpha Tau may
elect to update such forward-looking statements at some point in
the future, except as required by law, it disclaims any obligation
to do so, even if subsequent events cause its views to change.
These forward-looking statements should not be relied upon as
representing Alpha Tau's views as of any date subsequent to the
date of this press release.
Investor Relations ContactFor Alpha Tau:
IR@alphatau.comFor MIM: bcarruthers@mimsoftware.com
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024